Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Globus IPO Bid Is Good News For Spine Industry

This article was originally published in Start Up

Executive Summary

Globus Medical filed for an initial public offering of stock in March, making it the first spine company to test the public markets since TranS1 raised $86 million in its own IPO at the tail end of 2007.

You may also be interested in...



Globus Prepared for Trek with $110m from Clarus-led Group

Clarus Ventures placed an unusually big bet for the orthopedics industry by leading a syndicate of private equity investors in a $110 million Series E round in Globus Medical Inc. But the four-year-old company is well ahead of its peers with more than $100 million in sales and a line of fusion products on the market. The company faces the challenge of introducing a new line of non-fusion and biomaterial products if it hopes to grow into the industry leader its investors expects it to be.

Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment

Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.

FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials

Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel